These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://inesfhcy870840.blogoscience.com/45718601/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide